Open, parallel, prospective, randomized study between tamsulosin and tadalafil for male LUTS patients.

Open, parallel, prospective, randomized study between tamsulosin and tadalafil for male LUTS patients. - Kawasaki Study: Open, parallel, prospective, randomized study between tamsulosin and tadalafil for male LUTS patients.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000020362

Enrollment

400

Registered

2016-01-01

Start date

2016-01-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign prostatic hyperplasia

Interventions

Tadalafil (5mg) for 12 weeks Tamsulosin (0.2mg) for 12 weeks

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: male LUTS patients with BPH

Exclusion criteria

Exclusion criteria: Patients with ongoing administration of anti-cholinergic drugs, beta-3 receptor stimulants, anti-depressants, anxiolytic, and flavoxate hydrochloride. Patients ever administered with 5 alfa-reductase inhibitors and chlormadinone acetate.

Design outcomes

Primary

Measure	Time frame
International Prostate Symptom Score after 12 weeks of drug administration	—

Secondary

Measure	Time frame
Overactive Bladder Symptom Score (OABSS) IIEF5 Uroflowmetry, Residual urine volume	—

Countries

Japan

Contacts

Public ContactTakumi Takeuchi

Japan Labour Health and Welfare Organization, Kanto Rosai Hospital Department of Urology

takeuchit@kantoh.rofuku.go.jp044-411-3131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026